Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Feb 19, 2014
Insider Transaction Report
Form 4
Celeste Anthony C.
Director
Transactions
- Exercise/Conversion
Class A Common Stock
2014-02-14$3.56/sh+20,000$71,200→ 55,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2014-02-14−20,000→ 70,000 totalExercise: $3.56Exp: 2020-05-20→ Class A Common Stock (20,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2014-02-14−9,000→ 61,000 totalExercise: $4.41Exp: 2021-05-02→ Class A Common Stock (9,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2014-02-14−4,800→ 56,200 totalExercise: $4.41From: 2013-06-04Exp: 2021-05-02→ Class A Common Stock (4,800 underlying) - Exercise/Conversion
Class A Common Stock
2014-02-14$5.10/sh+30,000$153,000→ 35,000 total - Exercise/Conversion
Class A Common Stock
2014-02-14$4.41/sh+13,800$60,858→ 68,800 total - Exercise/Conversion
Employee Stock Option (right to buy)
2014-02-14−30,000→ 90,000 totalExercise: $5.10Exp: 2019-10-07→ Class A Common Stock (30,000 underlying)
Footnotes (3)
- [F1]Vesting commenced January 7, 2010 in twelve equal quarterly installments
- [F2]Vesting commenced June 20, 2010 in twelve equal quarterly installments
- [F3]4,500 exercisable on 5/12/12, and 4,500 exercisable on 5/12/13